Catalent Pharma Solutions Breaks Ground on $35-Million Expansion for Controlled Release

Catalent Pharma Solutions recently announced a major expansion of its controlled release drug manufacturing facility in Winchester, KY. The company is to invest nearly $35 million to expand the 100,000-sq-ft facility by almost 80,000 sq ft of modern manufacturing space, and will add as many as 90 new employees at the expanded site. Construction commenced on June 12, 2013, with a ceremony led by Kentucky Governor Steve Beshear and Catalent President and CEO John Chiminski. Catalent expects to complete the expansion by October 2014, and will welcome customers to tour the facility at that time.

The Governor of the Commonwealth of Kentucky, Steve Beshear, made the following statement, “Catalent is making tremendous strides forward in Winchester, and we’re excited to see such success for a global company in the Commonwealth. The numbers speak for themselves, with 90 new jobs and $35 million in investment, but this also shows the level of confidence that Catalent has in Kentucky’s high-quality workforce.”

Opened in 1992, Catalent’s Winchester facility has evolved into one of the industry’s premier sites for advanced oral controlled release drug formulation and manufacturing, launching over 100 products for Catalent’s pharmaceutical and consumer health customers. As industry demand for innovative dose forms continues to increase, Catalent is responding through expansion of its manufacturing premises and continuous improvement of equipment and workflows.

“Catalent is a fully integrated formulation, regulatory, and manufacturing solutions partner, helping pharmaceutical and consumer healthcare companies differentiate their products and reach markets faster,” said Steve Havel, General Manager of Catalent’s Winchester facility. “The expanded Winchester facility will provide our customers with enhanced access to custom equipment capabilities and our market-leading controlled release solutions and technologies.”

“The Winchester expansion comes on the heels of several significant investments Catalent has made in advanced delivery technologies globally. Catalent has continued to build on its global leadership in advanced drug development solutions and advanced delivery technologies with major recent investments in controlled release forms, including fluid bed capacity, OptiMelt hot melt extrusion, and OSDRC OptiDose advanced tableting technologies,” noted Mr. Chiminski. “As with Winchester, Catalent continues to invest to meet the most critical needs of the industry, including recently announced inhalation facility expansion in North Carolina, our recently completed biologics expansion in Wisconsin, and our two new ventures in China, which will focus on softgel technologies and clinical trial supplies.”

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. For more information, visit www.catalent.com.